XML 45 R19.htm IDEA: XBRL DOCUMENT v2.4.0.6
Business Segment Information
 9 Months Ended
Jan. 31, 2013
Segment Reporting [Abstract]  
Segment Reporting Disclosure [Text Block]

Note 13. Business Segment Information

 

The Company operates in two segments, POS and TOS. The accounting policies of the Company’s segments are the same as those described in Note 2 of the Company’s annual consolidated financial statements for the year ended April 30, 2012, as filed on Form 10-K. The Company evaluates performance of its segments based on profit or loss from operations before stock-based compensation expense, depreciation and amortization, interest expense, interest income, gain on sale of assets, special charges or benefits, and income taxes (“segment profit”). Management uses segment profit information for internal reporting and control purposes and considers it important in making decisions regarding the allocation of capital and other resources, risk assessment, and employee compensation, among other matters. The following tables summarize, for the periods indicated, operating results by business segment (in thousands):

 

          Translational              
    Personalized     Oncology     Unallocated        
    Oncology     Solutions     Corporate        
Three Months Ended January 31, 2013   Solutions (POS)     (TOS)     Overhead     Consolidated  
Net revenue   $ 473     $ 2,444     $ -     $ 2,917  
Direct cost of services     (661 )     (561 )     -       (1,222 )
Sales and marketing costs     (361 )     (220 )     -       (581 )
Other operating expenses     -       (627 )     (637 )     (1,264 )
Stock- based compensation expense (1)     -       -       (570 )     (570 )
                                 
Segment profit (loss)   $ (549 )   $ 1,036     $ (1,207 )   $ (720 )

 

          Translational              
    Personalized     Oncology     Unallocated        
    Oncology     Solutions     Corporate        
Three Months Ended January 31, 2012   Solutions (POS)     (TOS)     Overhead     Consolidated  
Net revenue   $ 649     $ 1,747     $ -     $ 2,396  
Direct cost of services     (528 )     (801 )     -       (1,329 )
Sales and marketing costs     (242 )     (175 )     -       (417 )
Other operating expenses     -       (851 )     (829 )     (1,680 )
Stock- based compensation expense (1)     -       -       (743 )     (743 )
                                 
Segment profit (loss)   $ (121 )   $ (80 )   $ (1,572 )   $ (1,773 )

 

          Translational              
    Personalized     Oncology     Unallocated        
    Oncology     Solutions     Corporate        
Nine Months Ended January 31, 2013   Solutions (POS)     (TOS)     Overhead     Consolidated  
Net revenue   $ 1,850     $ 4,631     $ -     $ 6,481  
Direct cost of services     (2,030 )     (1,740 )     -       (3,770 )
Sales and marketing costs     (495 )     (636 )     -       (1,131 )
Other operating expenses     -       (1,463 )     (2,418 )     (3,881 )
Stock- based compensation expense (1)     -       -       (1,934 )     (1,934 )
                                 
Segment profit (loss)   $ (675 )   $ 792     $ (4,352 )   $ (4,235 )

 

          Translational              
    Personalized     Oncology     Unallocated        
    Oncology     Solutions     Corporate        
Nine Months Ended January 31, 2012   Solutions (POS)     (TOS)     Overhead     Consolidated  
Net revenue   $ 1,837     $ 3,931     $ -     $ 5,768  
Direct cost of services     (1,463 )     (1,904 )     -       (3,367 )
Sales and marketing costs     (718 )     (626 )     -       (1,344 )
Other operating expenses     -       (2,419 )     (2,489 )     (4,908 )
Stock- based compensation expense (1)     -       -       (2,612 )     (2,612 )
                                 
Segment profit (loss)   $ (344 )   $ (1,018 )   $ (5,101 )   $ (6,463 )

 

(1) Stock compensation expense is shown separately and is excluded from direct costs of services, sales and marketing costs, and other operating expenses, as it is managed on a consolidated basis and is not used by management to evaluate the performance of its segments.

 

All of the Company’s revenue is recorded in the United States and substantially all of its long-lived assets are in the United States.